NRD
IOVA icon

Nebula Research & Development’s Iovance Biotherapeutics IOVA Stock Holding History

Nebula Research & Development’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-94,338
Closed -$314K – 1054
2025
Q1 		$314K Buy
94,338
+22,374
+31% +$115K 0.03% 746
2024
Q4 		$533K Sell
71,964
-17,826
-20% -$165K 0.06% 528
2024
Q3 		$843K Sell
89,790
-25,193
-22% -$239K 0.1% 363
2024
Q2 		$922K Buy
114,983
+92,571
+413% +$992K 0.15% 230
2024
Q1 		$332K Buy
+22,412
New +$261K 0.07% 492

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nebula Research & Development's IOVA Position: Q2 2025 in Review

Nebula Research & Development sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 94,338 shares — an estimated $314K sold.

Nebula Research & Development first reported a position in IOVA in Q1 2024 and held it in 5 quarters. The position peaked at $922K in Q2 2024. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Nebula Research & Development reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 94,338 Iovance Biotherapeutics shares in Q2 2025, an estimated $314K.
  • Nebula Research & Development first reported a position in Iovance Biotherapeutics in Q1 2024 and held it in 5 quarters.
  • Nebula Research & Development's Iovance Biotherapeutics position peaked at $922K in Q2 2024.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.